WAVE Life Sciences Ltd (FRA:1U5)
€ 12.8 -0.1 (-0.78%) Market Cap: 1.89 Bil Enterprise Value: 1.62 Bil PE Ratio: 0 PB Ratio: 13.52 GF Score: 41/100

Q4 2019 WAVE Life Sciences Ltd Earnings Call Transcript

Mar 02, 2020 / 01:00PM GMT
Release Date Price: €7.5 (-3.85%)
Operator

Good morning, and welcome to the Wave Life Sciences Fourth Quarter and Full Year 2019 Conference Call. (Operator Instructions) As a reminder, this call is being recorded and webcast.

I will now turn the call over to Kate Rausch, Head of Investor Relations at Wave Life Sciences. Please go ahead.

Kate Rausch
Wave Life Sciences Ltd. - Head of IR

Thank you, operator. Good morning, and thank you for joining us today to discuss our recent business progress and review Wave's fourth quarter and full year 2019 operating results. With me here today is Dr. Paul Bolno, our President and CEO; Dave Gaiero, Interim CFO; and Dr. Mike Panzara, Wave's Chief Medical Officer.

This morning, we issued a news release detailing our fourth quarter and full year results. Please note that this news release and the slide presentation that accompanies this webcast are available in the Investors section of our website, www.wavelifesciences.com.

Before we begin, I would like to remind you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot